Asciminib v léčbě pacienta se závažnou intolerancí dostupných inhibitorů tyrosinkinázy
| Title in English | Asciminib in the treatment of a patient with severe intolerance to available tyrosine kinase inhibitors |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.farmakoterapie.cz/c7675/asciminib-v-lecbe-pacienta-se-zavaznou-intoleranci-dostupnych-inhibitoru-tyrosinkinazy |
| Keywords | Asciminib; tyrosine kinase inhibitor intolerance |
| Attached files | |
| Description | For more than 20 years, the treatment of patients with chronic myeloid leukemia (CML) has been a picture of the success of targeted anticancer therapy, which began with the discovery of the first tyrosine kinase inhibitor (TKI) imatinib. Imatinib was soon followed by the introduction of other 2nd and 3rd generation TKIs. Available in the Czech Republic so far have been dasatinib, nilotinib, bosutinib and ponatinib. All of these TKIs bind to the ATP-binding region of the tyrosine kinase BCR::ABL1 and thus inhibit its phosphorylation. Thanks to these drugs, the life expectancy of CML patients is now comparable to that of the general population.1 However, some patients do not achieve a targeted response or do not tolerate treatment due to adverse events (AEs) when treated with their chosen TKI. AEs may be common to the entire group (class effect), but also more or less specific to individual TKIs.2 Treatment failure may be caused by the acquisition of a mutation in the BCR::ABL1 fusion gene, which in turn encodes a tyrosine kinase resistant to some TKIs.3 |
| Related projects: |